news
CHMP recommends Revolade for severe aplastic anaemia
27 July 2015 | By Victoria White
CHMP has adopted a positive opinion for Revolade for the treatment of patients with severe aplastic anaemia who have had an insufficient response to IST...
List view / Grid view
Novartis
news
Tafinlar and Mekinist combination therapy achieves regulatory milestones
27 July 2015 | By Victoria White
The CHMP has adopted a positive opinion for the combination of Tafinlar and Mekinist for the treatment of adult patients with advanced melanoma...
news
J&J and Norvatis to fight it out in the axSpA treatment space
22 July 2015 | By Victoria White
Stelara has progressed into Phase III development for axSpA and, following its anticipated approval, is forecast to achieve sales of $244.7 million in 2024...
news
Malaria treatment Coartem 80/480mg receives WHO prequalification
16 July 2015 | By Victoria White
Coartem 80/480mg has received WHO prequalification, making it the first high strength ACT antimalarial treatment available for public sector procurement...
news
FDA approves heart failure treatment Entresto
8 July 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Novartis' Entresto (sacubitril/valsartan) tablets for the treatment of heart failure with reduced ejection fraction.
news
New results show sustained efficacy with secukinumab over one year in psoriatic arthritis patients
29 June 2015 | By Victoria White
New one year results from the pivotal Phase III FUTURE 2 study of Novartis’ secukinumab in psoriatic arthritis (PsA) have been published.
news
Novartis acquires Spinifex Pharmaceuticals
29 June 2015 | By Victoria White
Novartis has entered into an agreement to acquire Spinifex - a company focused on developing a peripheral approach to treat neuropathic pain...
news
Panobinostat recommended by CHMP for EU approval to treat multiple myeloma
26 June 2015 | By Victoria White
The CHMP of the EMA have adopted a positive opinion for panobinostat capsules for the treatment of patients with multiple myeloma...
news
Arzerra improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukaemia
12 June 2015 | By Victoria White
Novartis has presented promising data from the Phase III COMPLEMENT 2 study of Arzerra in patients with replapsed chronic lymphocytic leukaemia...
news
Novartis’ Xolair improves quality of life by 78% for chronic spontaneous urticaria patients
12 June 2015 | By Victoria White
New analyses from pivotal Phase III studies show Xolair helps patients with Chronic Spontaneous Urticaria achieve improvements in quality of life measures...
news
Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients
10 June 2015 | By Victoria White
Novartis has announced new one-year study results from the MEASURE 2 pivotal Phase III study of secukinumab in ankylosing spondylitis (AS)...
news
Afinitor (everolimus) extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumours
22 May 2015 | By Victoria White
The Phase III study of everolimus in patients with advanced nonfunctional neuroendocrine tumours (NET) of GI or lung origin met its primary endpoint...
news
Novartis announces two positive US phase III programmes in COPD for QVA149 and NVA237
22 May 2015 | By Victoria White
Novartis has announced positive results from two pivotal Phase III clinical trial programmes for QVA149 and NVA237 in patients with moderate-to-severe COPD...
news
EC approves Zykadia for treatment of patients with ALK+ NSCLC
8 May 2015 | By Victoria White
The European Commission has approved Novartis’ Zykadia to treat adult patients with ALK+ NSCLC previously treated with crizotinib...
news
Investigational heart failure medicine LCZ696 receives Promising Innovative Medicine designation in the UK
23 April 2015 | By Victoria White
The MHRA has granted a PIM designation for Novartis’ investigational medicine for patients with heart failure with reduced ejection fraction, LCZ696...
